Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

Shares of NBRV stock opened at $0.00 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45. The firm’s 50 day simple moving average is $0.03. The firm has a market capitalization of $6,403.00, a PE ratio of 0.00 and a beta of 1.53.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.